VALBIOTIS news, videos and press releases
For more news please use our advanced search feature.
VALBIOTIS - More news...
VALBIOTIS - More news...
- Valbiotis presents its 2024 financial communication calendar
- Valbiotis sets out its commercial and clinical roadmap for 2024
- Valbiotis announces the success of its €15 M capital increase
- Valbiotis announces the launch of a capital increase
- Valbiotis announces the availability of an amendment to the Universal Registration Document
- Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
- VALBIOTIS SA:
- Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
- VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
- Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
- VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
- VALBIOTIS SA: Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM•63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance
- Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
- Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member
- Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
- Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023
- Valbiotis announces the release of the Universal Registration Document
- Valbiotis Announces Its Combined Shareholders General Meeting Will Be Held on May 2, 2023
- Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
- Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
- Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
- Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
- Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy
- Valbiotis Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University
- Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
- Valbiotis Announces the Availability of an Amendment to the Universal Registration Document
- Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
- Valbiotis Accelerates Its Marketing Strategy
- Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
- Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022